Cargando…

Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report

BACKGROUND: Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a limbic encephalitis that rarely presents as an isolated psychiatric syndrome. CASE PRESENTATION: A 70-year-old patient first presented with behavioral disorder including hyperactivity, euphoria, with disinhibition and accele...

Descripción completa

Detalles Bibliográficos
Autores principales: Porpiglia, Federica, Guillaume, Maxime, Bliaux, Evangeline, Psimaras, Dimitri, Decazes, Pierre, Guillin, Olivier, Rothärmel, Maud, Morin, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233061/
https://www.ncbi.nlm.nih.gov/pubmed/37275973
http://dx.doi.org/10.3389/fpsyt.2023.1168302
_version_ 1785052149785296896
author Porpiglia, Federica
Guillaume, Maxime
Bliaux, Evangeline
Psimaras, Dimitri
Decazes, Pierre
Guillin, Olivier
Rothärmel, Maud
Morin, Alexandre
author_facet Porpiglia, Federica
Guillaume, Maxime
Bliaux, Evangeline
Psimaras, Dimitri
Decazes, Pierre
Guillin, Olivier
Rothärmel, Maud
Morin, Alexandre
author_sort Porpiglia, Federica
collection PubMed
description BACKGROUND: Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a limbic encephalitis that rarely presents as an isolated psychiatric syndrome. CASE PRESENTATION: A 70-year-old patient first presented with behavioral disorder including hyperactivity, euphoria, with disinhibition and accelerated speech associated with severe insomnia and cognitive disorder. A manic episode was diagnosed and he received various psychotropic medications with no improvement. Invesitgations were negative (MRI showed T2 aspecific hyperintensities with no hyperintensities in limbic regions and EEG was normal). He was transferred to a nursing home, with a diagnosis of neurodegenerative condition. Later, he was referred to our unit for further investigations. A cerebral 18F-FDG-PET revealed an association of frontal hypometabolism and temporal and striatum hypermetabolism and CSF analysis revealed slightly increased white blood cell counts. Plasmatic anti-LGI1 antibodies were detected. The patient was treated with intra-venous immunoglobulin (IvIg) but showed no improvement. Second-line treatment (a combination of rituximab and cyclophosmphamide) was then administered for a year, leading to an improvement of neuropsychiatric symptoms and normalization of metabolic impairment on 18F-FDG-PET. CONCLUSION: In this report, we describe a novel case of a patient withanti-LGI1 encephalitis with a predominant long-term psychiatric presentation. An atypical presentation (such as atypical psychiatric symptoms, neurocognitive disorder, and hyponatremia) should prompt further investigations such as CSF analysis, considering that MRI and EEG may be normal. FDG-PET might be of interest but few data are available in the literature. Early treatment of anti-LGI1 encephalitis is crucial for overall prognosis and may delay the development of dementia in some cases.
format Online
Article
Text
id pubmed-10233061
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102330612023-06-02 Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report Porpiglia, Federica Guillaume, Maxime Bliaux, Evangeline Psimaras, Dimitri Decazes, Pierre Guillin, Olivier Rothärmel, Maud Morin, Alexandre Front Psychiatry Psychiatry BACKGROUND: Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a limbic encephalitis that rarely presents as an isolated psychiatric syndrome. CASE PRESENTATION: A 70-year-old patient first presented with behavioral disorder including hyperactivity, euphoria, with disinhibition and accelerated speech associated with severe insomnia and cognitive disorder. A manic episode was diagnosed and he received various psychotropic medications with no improvement. Invesitgations were negative (MRI showed T2 aspecific hyperintensities with no hyperintensities in limbic regions and EEG was normal). He was transferred to a nursing home, with a diagnosis of neurodegenerative condition. Later, he was referred to our unit for further investigations. A cerebral 18F-FDG-PET revealed an association of frontal hypometabolism and temporal and striatum hypermetabolism and CSF analysis revealed slightly increased white blood cell counts. Plasmatic anti-LGI1 antibodies were detected. The patient was treated with intra-venous immunoglobulin (IvIg) but showed no improvement. Second-line treatment (a combination of rituximab and cyclophosmphamide) was then administered for a year, leading to an improvement of neuropsychiatric symptoms and normalization of metabolic impairment on 18F-FDG-PET. CONCLUSION: In this report, we describe a novel case of a patient withanti-LGI1 encephalitis with a predominant long-term psychiatric presentation. An atypical presentation (such as atypical psychiatric symptoms, neurocognitive disorder, and hyponatremia) should prompt further investigations such as CSF analysis, considering that MRI and EEG may be normal. FDG-PET might be of interest but few data are available in the literature. Early treatment of anti-LGI1 encephalitis is crucial for overall prognosis and may delay the development of dementia in some cases. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10233061/ /pubmed/37275973 http://dx.doi.org/10.3389/fpsyt.2023.1168302 Text en Copyright © 2023 Porpiglia, Guillaume, Bliaux, Psimaras, Decazes, Guillin, Rothärmel and Morin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Porpiglia, Federica
Guillaume, Maxime
Bliaux, Evangeline
Psimaras, Dimitri
Decazes, Pierre
Guillin, Olivier
Rothärmel, Maud
Morin, Alexandre
Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title_full Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title_fullStr Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title_full_unstemmed Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title_short Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report
title_sort anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. a case report
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233061/
https://www.ncbi.nlm.nih.gov/pubmed/37275973
http://dx.doi.org/10.3389/fpsyt.2023.1168302
work_keys_str_mv AT porpigliafederica antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT guillaumemaxime antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT bliauxevangeline antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT psimarasdimitri antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT decazespierre antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT guillinolivier antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT rotharmelmaud antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport
AT morinalexandre antileucinerichgliomainactivated1encephalitisrevealedbyamanicepisodeinsightsfromfrontallobedysfunctioninneuropsychiatrythroughneuropsychologyandmetabolicimagingacasereport